Scholarlink

Background <p>Although dysregulation of iron metabolism is known to contribute to tumorigenesis, the upstream mechanisms driving iron overload in gastric cancer (GC) remain poorly understood. This research aims to elucidate the oncogenic role of eukaryotic translation initiation factor 3 subunit I (<i>EIF3I</i>) in GC and its impact on iron metabolism. </p> Methods <p><i>EIF3I</i> expression in GC was evaluated using clinical tissue samples and correlated with clinicopathological features. The functional impact of <i>EIF3I</i> on tumor progression was evaluated through both in vitro and in vivo assays. Molecular mechanisms were investigated using protein interaction studies, ubiquitination assays, and transcriptional analyses. A therapeutic peptide targeting <i>EIF3I</i>– was screened and tested in zebrafish and mice models. </p> Results <p><i>EIF3I</i> was significantly overexpressed in GC and associated with aggressive tumor phenotypes. <i>EIF3I</i> depletion suppressed GC cell proliferation and tumor growth, while its overexpression enhanced malignancy. Mechanistically, <i>EIF3I</i> stabilized yes-associated protein 1 (YAP) by directly interacting with it and preventing its ubiquitination and degradation by <i>STUB1</i>. This stabilization promoted YAP nuclear liquid–liquid phase separation and transcriptional activity, leading to increased expression of transferrin receptor 1 (<i>TFR1</i>), and consequent intracellular iron accumulation. Targeting the EIF3I interface on YAP with a screened peptide restored <i>STUB1</i>-mediated YAP degradation and significantly inhibited tumor growth in vitro and in vivo. </p> Conclusions <p><i>EIF3I</i> promotes GC progression by stabilizing YAP and reprogramming iron metabolism through the <i>EIF3I</i>–YAP-iron axis. Targeting this interaction represents a promising therapeutic strategy for GC.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

EIF3I reprograms iron metabolism to promote gastric cancer progression by stabilizing YAP

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月25日

查看全文
  • Yuan Si,
  • Dan Yang,
  • Haitao Zhang,
  • Sicheng Wang,
  • Liang Zhang,
  • Xiu Shen,
  • Kangrui Zhang,
  • Ke Xiang,
  • Xiangrong Zhan,
  • Xu Zhang,
  • Qingqing Yu,
  • Xuewen Liu,
  • Ying Liu

摘要

Background

Although dysregulation of iron metabolism is known to contribute to tumorigenesis, the upstream mechanisms driving iron overload in gastric cancer (GC) remain poorly understood. This research aims to elucidate the oncogenic role of eukaryotic translation initiation factor 3 subunit I (EIF3I) in GC and its impact on iron metabolism.

Methods

EIF3I expression in GC was evaluated using clinical tissue samples and correlated with clinicopathological features. The functional impact of EIF3I on tumor progression was evaluated through both in vitro and in vivo assays. Molecular mechanisms were investigated using protein interaction studies, ubiquitination assays, and transcriptional analyses. A therapeutic peptide targeting EIF3I– was screened and tested in zebrafish and mice models.

Results

EIF3I was significantly overexpressed in GC and associated with aggressive tumor phenotypes. EIF3I depletion suppressed GC cell proliferation and tumor growth, while its overexpression enhanced malignancy. Mechanistically, EIF3I stabilized yes-associated protein 1 (YAP) by directly interacting with it and preventing its ubiquitination and degradation by STUB1. This stabilization promoted YAP nuclear liquid–liquid phase separation and transcriptional activity, leading to increased expression of transferrin receptor 1 (TFR1), and consequent intracellular iron accumulation. Targeting the EIF3I interface on YAP with a screened peptide restored STUB1-mediated YAP degradation and significantly inhibited tumor growth in vitro and in vivo.

Conclusions

EIF3I promotes GC progression by stabilizing YAP and reprogramming iron metabolism through the EIF3I–YAP-iron axis. Targeting this interaction represents a promising therapeutic strategy for GC.